Application of azalomycin F to preparation of medicines for treating atopic dermatitis

A technology for atopic dermatitis and azamycin, applied in the application field of azamycin F in the preparation of drugs for treating atopic dermatitis, can solve the problems of lack of curative drugs and complicated pathogenesis, and achieve significant anti-atopic dermatitis. Effects on atopic dermatitis effects, good applications and development prospects

Active Publication Date: 2016-09-07
JIANGXI AGRICULTURAL UNIVERSITY
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The etiology and pathogenesis of AD are complex, involving multiple factors such as genetics, immunity, infection, environment, and spirit, and are closely related to the impairment of the skin barrier f

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of azalomycin F to preparation of medicines for treating atopic dermatitis
  • Application of azalomycin F to preparation of medicines for treating atopic dermatitis
  • Application of azalomycin F to preparation of medicines for treating atopic dermatitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] 1.1 Experimental animals and reagents

[0022] Experimental animals: 72 clean-grade healthy female Kunming mice, weighing 18-22 g, were purchased from the Experimental Animal Center of Nanchang University.

[0023] Reagent: Azamycin F 5a , Azamycin F 4a and azamycin F 3a Streptomyces Streptomyces hygroscopicus var .azalomyceticus , according to literature [2] Methods: The strains were fermented, and the fermentation products were prepared by solvent extraction, silica gel column chromatography and semi-preparative HPLC. The purity was 98.2%, 97.8% and 97.2%, respectively, and prepared with 0.15% CMC-Na aqueous solution before the experiment; 2, 4 - Dinitrofluorobenzene (DNFB) was purchased from Shanghai Chemical Reagent Company; mouse IL-4 and IgE ELISA kits were purchased from Invitrogen Company.

[0024] Establishment of atopic dermatitis model mice

[0025] 72 Kunming mice were randomly divided into model group, normal control group, azamycin F 5a group,...

Embodiment 2

[0058] 2.1 Experimental animals and reagents

[0059] Experimental animals: 91 clean-grade healthy female Kunming mice, weighing 18-22 g, were purchased from the Experimental Animal Center of Nanchang University.

[0060] Reagent: Azamycin F pure fractions A, B, C and D produced by Streptomyces Streptomyces hygroscopicus var .azalomyceticus , according to literature [2] The method is to carry out strain fermentation, and the fermentation product is obtained by solvent extraction and silica gel column chromatography; through HPLC analysis and determination, azamycin F in group A of azamycin F 3a , F 4a and F 5a The contents of Azamycin F in Group B were 61.7%, 33.5%, and 4.3%. 3a , F 4a and F 5a The contents of Azamycin F in group C were 13.5%, 73.2%, and 12.7%, respectively. 3a , F 4a and F 5a The contents of Azamycin F in Group D were 1.3%, 10.2%, and 87.8%. 4a and F 5a The contents of 2.9% and 96.7% were prepared with 0.15% CMC-Na aqueous solution before the ex...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of azalomycin F to the preparation of medicines for treating atopic dermatitis. Proved by experiments, the azalomycin F can obviously decrease the concentrations of IL-4 (Interleukin-4) and Ig E (Immunoglobulin E) in the serum of a model mouse suffering from the atopic dermatitis caused by DNFB (Dinitrofluorobenzene), inhibit the ear swelling of the mouse suffering from the atopic dermatitis and decrease the thymus index and the spleen index of the mouse, obviously improves the skin-lesion symptom of the mouse, and further presents the effect of being capable of radically treating the atopic dermatitis, thereby showing that the azalomycin F has an obvious anti-atopic-dermatitis function; the azalomycin F can be used for preparing the medicines for treating the atopic dermatitis; the favorable application and development prospect of the azalomycin F are shown.

Description

technical field [0001] The invention relates to the application of azalomycin F (Azalomycin F) in the preparation of medicines for treating atopic dermatitis. Background technique [0002] Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease, the main clinical manifestations are recurrent skin inflammation and itching. The etiology and pathogenesis of AD are complex, involving multiple factors such as genetics, immunity, infection, environment, and spirit, and are closely related to the impairment of the skin barrier function. Its treatment is one of the most difficult problems in clinical practice. Therefore, the research and development of effective drugs for the treatment of atopic dermatitis is particularly urgent. [0003] Azamycin F is a 36-membered polyhydroxy macrolide compound, including 3 main components Azamycin F 5a , F 4a and F 3a , has broad-spectrum anti-gram-positive bacteria and anti-fungal effects, and can be fermented by a variety of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/365A61P17/00A61P17/04
CPCA61K31/365A61K2300/00
Inventor 袁干军王一旻刘晓玲许雪杰王俊
Owner JIANGXI AGRICULTURAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap